CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Significant Increase in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 103,800 shares, an increase of 91.5% from the February 29th total of 54,200 shares. Based on an average daily trading volume, of 394,600 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.3% of the company’s shares are sold short.

CNS Pharmaceuticals Trading Down 2.2 %

CNSP stock traded down $0.01 during mid-day trading on Thursday, hitting $0.36. 180,889 shares of the company were exchanged, compared to its average volume of 412,811. The business has a fifty day simple moving average of $0.36 and a 200-day simple moving average of $1.15. CNS Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $4.40.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC purchased a new position in shares of CNS Pharmaceuticals in the second quarter valued at approximately $36,000. State Street Corp purchased a new position in shares of CNS Pharmaceuticals in the second quarter valued at approximately $50,000. Renaissance Technologies LLC purchased a new position in shares of CNS Pharmaceuticals in the first quarter valued at approximately $27,000. Smith Anglin Financial LLC purchased a new position in shares of CNS Pharmaceuticals in the fourth quarter valued at approximately $64,000. Finally, Vanguard Group Inc. boosted its stake in shares of CNS Pharmaceuticals by 145.6% in the fourth quarter. Vanguard Group Inc. now owns 58,369 shares of the company’s stock valued at $74,000 after purchasing an additional 34,604 shares during the period. Hedge funds and other institutional investors own 14.02% of the company’s stock.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.